Mon-Fri: 9.00 AM - 5.00 PM
(908) 296-5181
info@drbbthakar.com

Drug Development

Drug Development
interesting
4.3
Alzheimer’s Drug Development Using Ashwagandha (Withania somnifera) and Bramhi (Bacopa monnieri)
4.3
interesting
4.2
Summary rating from 1 user's marks. You can set own marks for this article - just click on stars above and press "Accept".
4.2

It is currently estimated by the Alzheimer’s foundation of America that 5.1 million Americans, may have Alzheimer’s disease. Current research from the National Institute on Aging indicates that the prevalence of Alzheimer’s disease doubles every five years beyond age 65. As our population ages, the disease impacts a greater percentage of Americans. The number of people age 65 and older will more than double between 2010 and 2050 to 88.5 million or 20 percent of the population; likewise, those 85 and older will rise three-fold, to 19 million, according to the U.S. Census Bureau. It is estimated that about a half million Americans younger than age 65 have some form of dementia, including Alzheimer’s disease. (This is referred to as young onset or early onset.) It is estimated that one to four family members act as caregivers for everyone with Alzheimer’s disease. There are many prescription drugs available, including extended release products. In the Ayurveda system of medicine, Ashwagandha and Bramhi have been used for dementia, as well Alzheimer’s and other neuro-pathologies. Our aim is to develop a good quality drug using these natural compounds for people to consume in a preventative capacity, using a unique and proprietary blend and drug delivery system. Our company is registered in Tampa and is affiliated with the Tampa Bay Technology incubator.